Get the Stockscreener App
4.94
1.00%
-0.05
After Hours:
5.03
0.09
+1.82%
Rezolute Inc stock is traded at $4.94, with a volume of 1.25M.
It is down -1.00% in the last 24 hours and down -1.98% over the past month.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
See More
Previous Close:
$4.99
Open:
$4.95
24h Volume:
1.25M
Relative Volume:
0.69
Market Cap:
$475.68M
Revenue:
-
Net Income/Loss:
$-81.49M
P/E Ratio:
-6.1063
EPS:
-0.809
Net Cash Flow:
$-73.48M
1W Performance:
+11.01%
1M Performance:
-1.98%
6M Performance:
+41.14%
1Y Performance:
-21.59%
1-Day Range:
$4.805
$5.13
1-Week Range:
$4.50
$5.395
52-Week Range:
$1.07
$11.46
Rezolute Inc Stock (RZLT) Company Profile
Name
Rezolute Inc
Sector
Industry
Phone
650-206-4507
Address
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Compare RZLT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.94 | 480.50M | 0 | -81.49M | -73.48M | -0.809 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-11-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-11-25 | Downgrade | Craig Hallum | Buy → Hold |
| Dec-11-25 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Aug-27-24 | Initiated | Guggenheim | Buy |
| Jul-17-24 | Initiated | BTIG Research | Buy |
| Jun-04-24 | Initiated | Craig Hallum | Buy |
| Apr-09-24 | Initiated | Maxim Group | Buy |
| Aug-02-22 | Resumed | Canaccord Genuity | Buy |
| Jun-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-08-21 | Initiated | ROTH Capital | Buy |
| May-27-21 | Initiated | Oppenheimer | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
View All
Rezolute Inc Stock (RZLT) Latest News
RZLT|Rezolute Inc|Price:4.930|Chg%:-0.060 - TradingKey
RZLT|Rezolute Inc|Price:4.990| - TradingKey
Rezolute Inc (RZLT) Balance Sheet - TradingKey
Rezolute Inc (RZLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rezolute Inc (RZLT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rezolute Inc (RZLT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rezolute Inc (RZLT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rezolute Inc (RZLT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rezolute Inc (RZLT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rezolute to Participate in the BTIG Virtual Biotechnology Conference - The Manila Times
Rezolute Management to Meet Investors Online July 28-29 - Stock Titan
Rezolute (RZLT) Q2 2026 Earnings: EPS Beat with 12.33% Surprise Amid No RevenuePeak Earnings Alert - dars.gov.et
Is Rezolute (NASDAQ:RZLT) In A Good Position To Deliver On Growth Plans? - Moomoo
Rezolute Inc (RZLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Rezolute Inc. (RZLT) Edges Higher Amid Positive Momentum, Testing Key ResistanceBollinger Expansion - dars.gov.et
Vivani Stock Puts These Obesity And Diabetes Treatment Stocks On The Radar - simplywall.st
Rezolute (RZLT) CMO disposes 3,062 shares in mandated RSU tax sale - Stock Titan
Form 4 Rezolute Inc For: 7 July By Investing.com - Investing.com Nigeria
Rezolute (RZLT) CEO logs automatic RSU tax-withholding share sale in Form 4 - Stock Titan
Rezolute (RZLT) CFO logs RSU tax sell-to-cover, retains 411,400 shares - Stock Titan
RZLTRezolute Inc Options - Finviz
RZLT News | REZOLUTE INC (NASDAQ:RZLT) - ChartMill
Price to earnings forward of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Price to book forward of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Price to earnings forward of Rezolute, Inc. – DUS:6HV1 - TradingView
Enterprise value to revenue forward of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Enterprise value to revenue forward of Rezolute, Inc. – DUS:6HV1 - TradingView
Enterprise value to EBITDA forward of Rezolute, Inc. – DUS:6HV1 - TradingView
Enterprise value to EBIT forward of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Price to sales forward of Rezolute, Inc. – NASDAQ:RZLT - TradingView
Enterprise value to EBIT forward of Rezolute, Inc. – DUS:6HV1 - TradingView
Price to sales forward of Rezolute, Inc. – DUS:6HV1 - TradingView
Rezolute, Inc. Actuals & Estimates (NASDAQ:RZLT) - TradingView
RZLT Forecast — Price Target — Prediction for 2027 - TradingView
A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $5 to $14 - Moomoo
Rezolute Inc (RZLT) Valuation: PE, PB & Fair Value Analysis - TradingKey
RZLT stock plummets 79% month to date: Here's what you need to know - MSN
RZLT Q1 2026 Earnings: EPS Beats Estimates Amid Ongoing Clinical DevelopmentHigh Growth Earnings - dars.gov.et
Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth - Streetwise Reports
Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data - Streetwise Reports
Rezolute data: 75% of tumor HI patients came off IV dextrose at ENDO - Stock Titan
Rezolute Inc (RZLT) Institutional Confidence - TradingKey
Rezolute presents hyperinsulinism data at endocrine meeting - Investing.com UK
Rezolute presents hyperinsulinism data at endocrine meeting By Investing.com - Investing.com South Africa
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society - The Manila Times
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug ... - Caledonian Record
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail
Rezolute Inc Stock (RZLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):